ArriVent BioPharma Plans $75 Million Public Offering
MT Newswires Live
Jul 02
ArriVent BioPharma (AVBP) said late Tuesday it plans a $75 million public offering of common shares and pre-funded warrants.
The company said it will offer underwriters a 30-day overallotment option to buy up to an additional 15% of the total offering size.
ArriVent will use the net proceeds to advance activities related to its firmonertinib drug to treat non-squamous non-small cell lung cancer, as well as for general corporate purposes, the company said.
Shares of the company fell 5.7% during after-hours activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.